ArticleBreast cancer (Dove Medical Press)2026
SLAMF8 Promotes M2 Polarization of Macrophages and Enhances Breast Cancer Proliferation.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is characterized by a complex pathogenesis and diverse clinical manifestations. Tumor-associated macrophages (TAMs) play a pivotal role in tumorigenesis, metastasis, and response to anticancer therapies. This study aimed to analyze the functional role of signaling lymphocytic activation molecule family 8 (SLAMF8) in TAMs and its impact on breast cancer cell proliferation. Methods: The SLAMF8 silencing in THP-1 cells was established by transfection with SLAMF8 shRNA lentiviral particles, and the THP-1 cells were induced to M0 macrophages or M2 macrophages. The M2 macrophage markers, CD11b+CD163, CD206, and IL-10, were measured by flow cytometry and Western blotting. The induced macrophages were cocultured with breast cancer cells (MCF-7 and MDA-MB-231) using a transwell insert. The viability and migration of cancer cells were measured using CCK-8 and transwell migration. The STAT6 and NF-κB pathways were measured using Western blotting. In vivo, mice were co-injected with breast cancer cells and the THP-1-derived macrophages to observe the tumor growth. The NF-κB pathway in tumor tissues was measured by immunohistochemistry and Western blotting. Results: The SLAMF8 silencing significantly downregulated the number of THP-1-derived M2 macrophages. The viability, migration, and the STAT6 and NF-κB pathways of breast cancer cells were significantly enhanced after co-culture with M2 macrophages compared to co-culture with M0 macrophages. However, the SLAMF8 silencing markedly suppressed the promoting effects of M2 macrophage co-culture on the above factors in cancer cells. In line with the in-vitro results, co-injection with M2 macrophages significantly promoted the tumor growth. Moreover, the SLAMF8 silencing in M2 macrophages downregulated the tumor growth compared with that of cancer cells co-injected with M2 macrophages without SLAMF8 silencing. Conclusion: This study showed that SLAMF8 silencing downregulated M2 macrophage polarization and weakened the promoting effects of M2 macrophages on breast cancer cells, suggesting a promising therapeutic strategy for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.